Filtered By:
Education: Study
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 2305 results found since Jan 2013.

Simultaneous thrombosis of 2 vascular territories: is thrombolytic therapy a better option?
We have read with great interest the article by Akyuz and colleagues in the American Journal of Emergency Medicine and congratulate them for their observation. Their case exemplifies the concurrent occurrence of ST-segment elevation myocardial infarction (STEMI) and posterior circulation stroke that was eventually managed with thrombolytic therapy. Simultaneous thrombosis of 2 distant vascular territories is a rare and complicated clinical scenario. In these instances, there is usually an underlying cause linking both thrombotic events rather than being a mere coincidence. We have previously described the myocardial infarc...
Source: The American Journal of Emergency Medicine - July 1, 2013 Category: Emergency Medicine Authors: Hesham R. Omar, Devanand Mangar, Enrico M. Camporesi Tags: Correspondence Source Type: research

CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study Genetics
Conclusions There were significant differences in recurrent stroke by CYP2C19 genotype-inferred metabolizer status in white subcortical stroke patients receiving dual antiplatelet therapy with aspirin and clopidogrel, consistent with cardiovascular studies on CYP2C19 and clopidogrel; however, the bleeding risk that led to early termination of the antiplatelet arm of the SPS3 trial does not appear to be explained by CYP2C19 genotype. This study was relatively underpowered; therefore, these findings should be interpreted with caution and warrant replication. Clinical Trial Registration URL: www.clinicaltrials.gov. Unique id...
Source: JAHA:Journal of the American Heart Association - May 27, 2015 Category: Cardiology Authors: McDonough, C. W., McClure, L. A., Mitchell, B. D., Gong, Y., Horenstein, R. B., Lewis, J. P., Field, T. S., Talbert, R. L., Benavente, O. R., Johnson, J. A., Shuldiner, A. R. Tags: Genetics Source Type: research

Drug ‐eluting stents versus coronary artery bypass grafting for left‐main coronary artery disease
ConclusionsWhen compared with CABG, DES‐PCI for LMCAD was associated with increases in RRV and the composite of death, MI, and RRV (with/without stroke), despite no differences in mortality, MI, stroke, and the composite of death and MI (with/without stroke).
Source: Catheterization and Cardiovascular Interventions - August 11, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Hisato Takagi, Tomo Ando, Takuya Umemoto, Tags: CORONARY ARTERY DISEASE Source Type: research

1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry
Conclusions Intermediate to high-risk women enrolled in this first ever all-women contemporary TAVR registry experienced a 1-year VARC-2 composite efficacy endpoint of 16.5%, with a low incidence of 1-year mortality and stroke. Prior revascularization and EuroSCORE I were independent predictors of the VARC-2 efficacy endpoint, whereas EuroSCORE I, baseline atrial fibrillation, and prior percutaneous coronary intervention were independent predictors of the 1-year death or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 1, 2018 Category: Cardiology Authors: Chieffo, A., Petronio, A. S., Mehilli, J., Chandrasekhar, J., Sartori, S., Lefevre, T., Presbitero, P., Capranzano, P., Tchetche, D., Iadanza, A., Sardella, G., Van Mieghem, N. M., Meliga, E., Dumonteil, N., Fraccaro, C., Trabattoni, D., Mikhail, G., Shar Tags: Focus on Cardiovascular Outcomes Among Women Source Type: research

DES reduce the risk of ISR in patients with ICAS compared to BMS
Dr. Snipe Clinical question: In patients with symptomatic high-grade intracranial atherosclerotic stenosis (ICAS), does the use of a drug-eluting stent (DES) reduce the incidence of in-stent restenosis (ISR) and stroke recurrence compared to using a bare-metal stent (BMS)? Background: ICAS is a common cause of stroke in North America (accounting for 8-10% of strokes) and is even more common in Asia (accounting for 30-50% of strokes). In previous trials, aggressive medical management was found to be the superior first-line treatment, but intracranial stenting is growing in popularity and safety. DES is known to reduce ISR ...
Source: The Hospitalist - August 1, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: CAD & Atherosclerosis Critical Care In the Literature Source Type: research

Influence of diabetes mellitus on long-term outcomes of patients with unprotected left main coronary artery disease treated with either drug-eluting stents or coronary artery bypass grafting.
This study was conducted to evaluate the impact of diabetes on patients with ULMCA disease treated with either percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG).A total of 922 patients with ULMCA disease who received drug-eluting stent (DES) (n = 465) implantation or underwent CABG (n = 457) were retrospectively analyzed. We compared the effects of these 2 treatments on clinical outcomes (death, myocardial infarction, stroke, repeat revascularization, and the composite of death, myocardial infarction, or stroke), according to diabetic status.During the median follow-up of 7.1 years (interqu...
Source: International Heart Journal - June 3, 2015 Category: Cardiology Tags: Int Heart J Source Type: research

Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial
CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT02100722.PMID:37602376 | DOI:10.1161/CIRCULATIONAHA.123.065770
Source: Circulation - August 21, 2023 Category: Cardiology Authors: Frederik M Zimmermann Victoria Y Ding Nico H J Pijls Zsolt Piroth Albert H M van Straten Laszlo Szekely Giedrius Davidavicius Gintaras Kalinauskas Samer Mansour Rajesh Kharbanda Nikolaos Östlund-Papadogeorgos Adel Aminian Keith G Oldroyd Nawwar Al-Attar Source Type: research

Percutaneous coronary intervention versus coronary artery bypass graft for stable angina: Meta-regression of randomized trials
Conclusion: PCI significantly reduces the risk of stroke compared to CABG particularly in female patients: however the risk of revascularization is increased with PCI, especially in women and in those with diabetes.
Source: Contemporary Clinical Trials - May 1, 2014 Category: Radiology Authors: Fabrizio D'Ascenzo, Umberto Barbero, Claudio Moretti, Tullio Palmerini, Diego Della Riva, Andrea Mariani, Pierluigi Omedè, James J. DiNicolantonio, Giuseppe Biondi-Zoccai, Fiorenzo Gaita Tags: Study Design, Statistical Design, Study Protocols Source Type: research

Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Conclusions: Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel. Ticagrelor also reduces the need for GPIIb/IIIa inhibitors. However, no significant difference was observed in the risk of bleeding between the 2 groups.
Source: Journal of Cardiovascular Pharmacology - August 1, 2016 Category: Cardiology Tags: Original Article Source Type: research

Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis.
CONCLUSIONS: According to the results of this analysis, DAPT might have to be cautiously be used following PCI in a population of patients with thrombocytopenia at baseline due to the significantly higher bleeding rate including gastro-intestinal, intra-cranial bleeding and hemorrhagic stroke. Hence, special care might have to be taken when considering anti-platelet agents following PCI in these high risk patients. However, considering the present limitations of this analysis, this hypothesis will have to be confirmed in future trials. PMID: 32334636 [PubMed - as supplied by publisher]
Source: BMC Pharmacology and Toxicology - April 27, 2020 Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research

Short ‐term and long‐term outcomes of revascularization interventions for patients with severely reduced left ventricular ejection fraction: a meta‐analysis
ConclusionsAmong patients with severely reduced LV ejection fraction, CABG resulted in a lower mortality rate and an increased risk of stroke.
Source: ESC Heart Failure - December 3, 2020 Category: Cardiology Authors: Junyu Pei, Xiaopu Wang, Zhenhua Xing, Keyang Zheng, Xinqun Hu Tags: Original Research Article Source Type: research